Standards For Early Alzheimer’s Drugs Adapted, Not Loosened, FDA’s Katz Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A draft guidance for development of drugs to treat early Alzheimer’s disease does not loosen agency standards, FDA’s neurology products chief asserts. Rather, it is an attempt to establish criteria tailored to the population.